Università degli Studi di Padova

SBA Sistema Bibliotecario di Ateneo

Biblioteca di scienze del Farmaco

LABORATORIO DI RICERCA BIBLIOGRAFICA PER GLI STUDENTI DI FARMACIA

TERZO MODULO

LE BANCHE DATI PER LE SCIENZE DEL FARMACO

Document Delivery (DD)

L'articolo che state cercando non è disponibile a Padova?
Ci pensiamo noi a recuperarlo con il servizio di fornitura documenti!



Per informazioni sul servizio:

https://biblio.unipd.it/usa-le-biblioteche/fornitura-documenti

COSA CERCHI

Libri | Riviste e articoli | Testi d'esame | Tesi

IN EVIDENZA

CODIFA - L'Informatore Farmaceutico

Codifa è un motore di ricerca per tutti i prodotti medicinali, salutistici e veterinari commercializzati in Italia. Contiene informazioni su: farmaci, parafarmaci, prodotti salutistici, interazioni tra farmaci, alimenti e prodotti naturali, nonché informazioni sulle aziende del settore presenti in Italia.

Auth-proxy

AdisInsight

Contiene informazioni scientifiche sui farmaci e il loro sviluppo sul mercato a livello internazionale (inclusi trial e brevetti). Contiene anche sezioni dedicate all'impiego dei farmaci in relazione al trattamento delle malattie e sul processo di decision-making relativo alla produzione e messa in commercio dei farmaci.

Auth-proxy

Medicamenta

Fonte di informazione esauriente sui principi attivi e su ogni molecola impiegata in terapia: denominazione e sinonimi, caratteristiche chimico-fisiche, saggi di identificazione e purezza, proprietà farmacologiche, tossicità, indicazioni terapeutiche, posologia, effetti collaterali, controindicazioni e precauzioni d'uso, interazioni e sovradosaggio.

Solo in Biblioteca

Micromedex

Multibanca dati fulltext su farmacologia (Drugdex, Martindale, Interaction Checking, Italian Drug Database), teratogenesi e rischio riproduttivo (Reprorisk), medicina alternativa (Alternative medicine), medicina generale (Disea).

Solo in Biblioteca

Università degli Studi di Padova

SBA Sistema Bibliotecario di Ateneo

Biblioteca di scienze del Farmaco

Tra le risorse più importanti e utili che l'Ateneo mette a disposizione per la ricerca scientifica troviamo le banche dati.
Le banche dati si possono occupare di una o più aree disciplinari e soprattutto forniscono informazioni bibliografiche e fattuali.

Come trovarle? Utilizzando GalileoDiscovery!

https://galileodiscovery.unipd.it/discovery/search?vid=39UPD_INST:VU1



Posso fare una ricerca per Categoria > selezionando Scienze del Farmaco trovo in elenco 35 banche dati specifiche

Banca dati bibliografica e citazionale:
archivio digitale aggiornato di letteratura scientifica (articoli di riviste scientifiche, atti di congressi, monografie etc.,)
Dotata di sistemi di interrogazione più o meno raffinati, forniscono anche dati bibliometrici come le citazioni

Banca dati fattuale:
archivio digitale di schede tecniche e informative più schematizzate e riassuntive. Queste banche dati forniscono informazioni fattuali, quali dati, definizioni, formule, indicatori, normativa ed altro di una o più aree disciplinari.

Piccola guida alle principali e più utilizzate banche dati per le scienze del farmaco

Banche dati di varie tipologie: bibliografiche, citazionali e banche dati fattuali

- SCOPUS
- PUBMED
- INFORMATORE FARMACEUTICO (codifa)
- MICROMEDEX
- WEB OF SCIENCE
- PUBCHEM
- DRUGBANK
- ADISINSIGHT
- MEDICAMENTA e European Pharmacopoeia

Pubmed

Tra le più importanti banche dati bibliografiche a livello internazionale.
E' una risorsa gratuita per la ricerca e il recupero di riferimenti bibliografici ad articoli scientifici e ad altri documenti di ambito biomedico e biologico.

https://pubmed.ncbi.nlm.nih.gov/?otool=iitudplib

SCOPUS

Banca dati bibliografica e citazionale di ambito multidisciplinare a pagamento.

Al suo interno troviamo dati bibliografici (titolo, abstract…) di articoli, atti di convegno…

Accessibile dalle sedi universitarie e da casa via EduVPN o SSO

Scopus

https://www.scopus.com/search/form.uri?display=basic#basic


Scopus
Search
Sources
Lists
SciVal
Create account
Sign in
Start exploring
Discover the most reliable, relevant, up-to-date research. All in one place.
Brought to you by
University of Padua, Library+shibboleth
Documents
Authors
Affiliations
Search tips
Search within
Article title, Abstract, Keywords
Search documents *
Add search field
Add date range
Advanced document search
Search



17,208 document results

TITLE-ABS-KEY (covid AND vaccine)

Edit Save Set alert

Search within results...

Refine results

Limit to Exclude

Open Access

- All Open Access (14,306)
- Gold (5,593)
- Hybrid Gold (1,299)
- Bronze (5,783)
- Green (10,550)

Learn more

Year

- 2022 (53)
- 2021 (12,379)
- 2020 (4,771)
- 2019 (4)
- 2007 (1)

Documents | Secondary documents | Patents | View Mendeley Data (3748)

Analyze search results | Show all abstracts | Sort on: Cited by (highest)

All | Export | Download | View citation overview | View cited by | Add to List | ...

	Document title	Authors	Year	Source	Cited by
1	Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine *Open Access*	Polack, F.P., Thomas, S.J., Kitchin, N., (...), Jansen, K.U., Gruber, W.C.	2020	New England Journal of Medicine 383(27), pp. 2603-2615	2393
	View abstract | Cerca con Galileo | View at Publisher | Related documents				
2	Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine *Open Access*	Baden, L.R., El Sahly, H.M., Essink, B., (...), Miller, J., Zaks, T.	2021	New England Journal of Medicine 384(5), pp. 403-416	1487
	View abstract | Cerca con Galileo | View at Publisher | Related documents				
3	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing *Open Access*	Gordon, D.E., Jang, G.M., Bouhaddou, M., (...), Shoichet, B.K., Krogan, N.J.	2020	Nature 583(7816), pp. 459-468	1338
	View abstract | Cerca con Galileo | View at Publisher | Related documents				

Document type
Article • *Bronze Open Access* • *Green Open Access*

Source type
Journal

ISSN
00284793

DOI
10.1056/NEJMoa2034577

View more

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

Polack F.P.[a], Thomas S.J.[c], Kitchin N.[a], Absalon J.[d], Gurtman A.[d], Lockhart S.[a], Perez J.L.[f], Marc G.P.[b], Moreira E.D.[h], Zerbini C.[i], Bailey R.[a], Swanson K.A.[d]

Show additional authors | Save all to author list

[a] Fundacion INFANT, Buenos Aires, Argentina
[b] ITrials-Hospital Militar Central, Buenos Aires, Argentina
[c] State University of New York, Upstate Medical University, Syracuse, NY, United States
[d] Vaccine Research and Development, Pfizer, Pearl River, NY, United States

View additional affiliations

2.584 Citations in Scopus | 383 Views count | View all metrics

Full text options

Abstract
Indexed keywords
Drug tradenames
SciVal Topics
Chemicals and CAS Registry Numbers
Metrics
Funding details

Abstract

BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 fulllength spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS A total of 43, 548 participants underwent randomization, of whom 43, 448 received injections: 21, 720 with BNT162b2 and 21, 728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9

(2022) Food Control

The behavioral immune system and vaccination intentions during the coronavirus pandemic
Karlsson, L.C. , Soveri, A. , Lewandowsky, S.
(2022) Personality and Individual Differences

Novel nucleocapsid protein-targeting phenanthridine inhibitors of SARS-CoV-2
Wang, Y.-T. , Long, X.-Y. , Ding, X.
(2022) European Journal of Medicinal Chemistry

View all 2584 citing documents

Inform me when this document is cited in Scopus:

Set citation alert >

Related documents

Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults
Mulligan, M.J. , Lyke, K.E. , Kitchin, N.
(2020) Nature

Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study
Li, J. , Hui, A. , Zhang, X.
(2021) Nature Medicine

Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera
Xie, X. , Liu, Y. , Liu, J.
(2021) Nature Medicine

View all related documents based on references

Find more related documents in Scopus based on:

Web Of Science (WOS)

Altra importante banca dati bibliografica e citazionale di ambito multidisciplinare a pagamento dove ricercare la letteratura scientifica.

Accessibile dalle sedi universitarie e da casa solo via EduVPN

Clarivate Web of Science™

https://www.webofscience.com/wos/woscc/basic-search


Clarivate
English
Products
Web of Science
Search
Sign In
Register
MENU
DOCUMENTS
RESEARCHERS
Smart Search BETA
Advanced Search
Search for documents by entering topics, authors, institutions, funders
fentanyl
Search
Jump back into your research - try out our new personalized homepage dashboard.
Don't have an account? Register for a new account
Sign in to access
CRUI - Universita degli Studi di Padova
Clarivate


Smart Search › Results
1,516 results from Web of Science Core Collection for:
Analyze Results
Citation Report
Create Alert
fentanyl
Search
Add Keywords
Quick add keywords:
+ FENTANYL
+ NEUROMUSCULAR RELAXANTS ROCURONIUM
+ MEASUREMENT TECHNIQUE NEUROMUSCULAR BLOCKADE
+ ANALGESICS OPIOID FEN
Publications
You may also like...
Copy query link
Refine results
Search within results...
Quick Filters
Review Article 2
Open Access 425
Enriched Cited References 4
Publication Years
2023 44
2022 30
2021 26
0/1,516
Add To Marked List
Export
Sort by: Relevance
1 of 31
1 Determination of fentanyl in human plasma and fentanyl and norfentanyl in human urine using LC-MS/MS
Semantic search result
Huynh, NH; Tyrefors, N; (...); Johansson, M
15th International Symposium on Pharmaceutical and Biomedical Analysis
Apr 29 2005 | JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS 37 (5) , pp.1095-1100
Fentanyl, a potent analgesic drug, has traditionally been used intravenously in surgical or diagnostic operations. Formulations with fentanyl in oral transmucosal delivery system and in transdermal depot-patch have also been developed against breakthrough pain in cancer patients. In this report, LC-MS/MS methods to determine fentanyl in human plasma as well as fentanyl and its main metabolite, ... Show more
Full Text at Publisher
54 Citations
15 References
Related records
2 Fentanyl concentrations in 23 postmortem cases from the Hennepin County Medical Examiner's Office
51

Informatore farmaceutico (Codifa)

È il motore di ricerca per tutti i prodotti medicinali, salutistici e veterinari commercializzati in Italia.

Accessibile dalle sedi universitarie e da casa solo via EduVPN

(Attenzione 1 accesso alla volta)

Codifa L'INFORMATORE FARMACEUTICO

https://www.codifa.it



E' possibile visualizzare gli RCP dei farmaci, le precauzioni da valutare e le interazioni.
Le informazioni riportate sono aggiornate in tempo reale attraverso i contatti diretti con le aziende farmaceutiche e parafarmaceutiche e l'utilizzo di fonti ufficiali quali AIFA, EMA, Gazzetta Ufficiale e Ministero della Salute.

ASPIRINA

Bayer S.p.A.
325 mg 10 compresse

Ultimo aggiornamento il: 20/07/2021

Stampa

Precauzioni da valutare

I simboli sono da interpretarsi come segnalazione di precauzione nell'uso, di valutazione del prodotto e dell'eventuale rapporto rischio beneficio

N° INTERAZIONI TOTALI:276

17 Interazione clinicamente rilevante

136 Interazione rilevante gestibile con aggiustamento del dosaggio

AIC	004763254
TITOLARE	Bayer S.p.A.
CLASSE	C
RICETTA	OTC - medicinale di automedicazione
ATC	N02BA01 - Acido acetilsalicilico
PRINCIPIO ATTIVO	acido acetilsalicilico
GRUPPO TERAP.	Antiaggreganti piastrinici, Antipiretici, Analgesici FANS
PREZZO	€ 6,3
FORMA FARMACEUTICA	compressa
PIANO TERAPEUTICO	No
PHT	No

RCP

- 1 - DENOMINAZIONE DEL MEDICINALE
- 2 - COMPOSIZIONE QUALITATIVA E QUANTITATIVA
- 3 - FORMA FARMACEUTICA
- 4 - INFORMAZIONI CLINICHE
- 4.1 - Indicazioni terapeutiche
- 4.2 - Posologia e modo di somministrazione
- 4.3 - Controindicazioni
- 4.4 - Avvertenze speciali e precauzioni d'impiego
- 4.5 - Interazioni con altri medicinali ed altre forme d'interazione
- 4.6 - Fertilità, gravidanza e allattamento
- 4.7 - Effetti sulla capacità di guidare veicoli e sull'uso di macchinari
- 4.8 - Effetti indesiderati
- 4.9 - Sovradosaggio
- 5 - PROPRIETA' FARMACOLOGICHE
- 5.1 - Proprietà farmacodinamiche
- 5.2 - Proprietà farmacocinetiche
- 5.3 - Dati preclinici di sicurezza
- 6 - INFORMAZIONI FARMACEUTICHE
- 6.1 - Elenco degli eccipienti
- 6.2 - Incompatibilità
- 6.3 - Periodo di validità
- 6.4 - Precauzioni particolari per la conservazione
- 6.5 - Natura e contenuto del contenitore
- 6.6 - Precauzioni particolari per lo smaltimento e la manipolazione
- 7 - TITOLARE DELL'AUTORIZZAZIONE ALL'IMMISSIONE IN COMMERCIO
- 8 - NUMERO(I) DELL'AUTORIZZAZIONE ALL'IMMISSIONE IN COMMERCIO
- 9 - DATA DELLA PRIMA AUTORIZZAZIONE/RINNOVO DELL'AUTORIZZAZIONE
- 10 - DATA DI REVISIONE DEL TESTO
- 11 DOSIMETRIA
- 12 ISTRUZIONI PER LA PREPARAZIONE DI RADIOFARMACI


SISTEMA SUPPORTO PRESCRIZIONE
Codifa safecare
1
Area
2
3
4
5
Seleziona l'area o l'apparato inerente la patologia di cui è affetto il paziente
Apparato cardiovascolare
Apparato respiratorio
Dermatologia
Endocrinologia e metabolismo
Gastroenterologia
Malattie infettive
Nefrologia e urologia
Neurologia
Oculistica
Oncologia
Ostetricia e ginecologia
Otorinolaringoiatria
Psichiatria
Reumatologia e immunologia
Avanti


SISTEMA SUPPORTO PRESCRIZIONE
Codifa safecare
1
2
Patologia
3
4
5
Seleziona la patologia di cui è affetto il paziente
Asma cronica
Broncopneumopatia Cronica Ostruttiva - Acutizzazione
Ipertensione polmonare
Tosse
Indietro
Avanti


8
BOSENTAN
DA VALUTARE
BOSENTAN ACCORD
• 125 mg 56 compresse rivestite con film in blister
• 62,5 mg 56 compresse rivestite con film
Interagisce con
REAGILA (CARIPRAZINA) Enterale (per bocca)
Interazione di rilevanza clinica, è meglio evitare la cosomministrazione
BOSENTAN AUROBINDO
• 125 mg 56 compresse rivestite con film
• 62,5 mg 56 compresse rivestite con film
Interagisce con
REAGILA (CARIPRAZINA) Enterale (per bocca)
Interazione di rilevanza clinica, è meglio evitare la cosomministrazione

AdisInsight

Banca dati a pagamento che raccoglie dati su farmaci in sviluppo a livello globale, relativi a studi clinici e a casi di reazioni avverse ai farmaci. Presenta il panorama completo a partire dagli stadi precoci di ricerca fino allo sviluppo clinico e agli aspetti di safety successivamente osservati dalla messa in commercio.

Accessibile dalle sedi universitarie e da casa solo via EduVPN

Adis Insight

https://adisinsight.springer.com/


AdisInsight
AskAdis AI New
Pharma Insight Reports New
Dashboards Beta
My Workspace
Contact Us
Help
Search
by Drug Name
Atu027
Advanced search
Structure search
Last 5 Searches
Refine Your Search
Indication
Phase
Development Location
Biomarker Name
Target
Mechanism Of Action
Drug Class
1 Drugs
3 Trials
0 Safety Reports
3 Deals
0 Patents
Show Query
Share Query
Edit Query
Export
Analysis
Print Selected 0 drugs
Showing 1 of 1 drugs
Explore Graphical View
View by: List View
Sort by: Update date
Atu 027
28 Feb 2020
Protein kinase N3 inhibitors; RNA interference
Originator: Atugen AG
Inactive Indications on highest development phases
Discontinued: Head and neck cancer; Pancreatic cancer; Solid tumours

At a glance

Originator	Atugen AG
Developer	Silence Therapeutics; Silence Therapeutics AG
Class	Antineoplastics; Small interfering RNA
Mechanism of Action	Protein kinase N3 inhibitors; RNA interference
Orphan Drug Status	No
New Molecular Entity	Yes
Available For Licensing	Yes

Highest Development Phases

Discontinued	Head and neck cancer; Pancreatic cancer; Solid tumours

Most Recent Events

28 Feb 2020	No recent reports of development identified for preclinical development in Head-and-neck-cancer in United Kingdom (IV, Infusion)
04 Nov 2017	Discontinued - Phase-I for Solid tumours (Late-stage disease) in Germany (IV)
04 Nov 2017	No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease) in Germany (IV, Infusion)

Table of Contents

Scientific Summary

Pharmacokinetics

Results from 33 patients in a phase I trial of seven escalating doses of Atu 027, showed that there was a dose-dependent increase in plasma siRNA and lipid levels, suggesting that there was no accumulation of Atu 027 during repeat treatment [12] [13] [28] .

Adverse Events

Results from 33 patients in a phase I trial of seven escalating doses of Atu 027, demonstrated that Atu 027 was generally well tolerated in patients with solid tumours. No dose-limiting toxicities or evidence of cytokine activation was observed [12] [13] [28] .The prospective recommended maximum tolerated dose of Atu 027 was established as 0.336 mg/kg [9] .

In its presentation in June 2015, Silence Therapeutics announced interim data from a phase IIa trial in pancreatic cancer. The safety data showed that adverse events were associated with administration of gemcitavine, but not with with Atu 027. Atu 027 was well tolerated.

Pharmacodynamics

Summary

In a dose-escalating phase I study, Atu 027 0.18 mg siRNA/kg achieved the same blood plasma siRNA concentration that had been sufficient to silence the expression of PKN-3 in preclinical studies. Of the 11 doses trialled, dose levels of 6 and higher caused a reduction of soluble VEGF-R1 (sFLT-1) levels in 7 of 9 patients [9] .

Atu 027 reduced the growth and metastasis of human pancreatic cancer and improved the antineoplastic efficacy of gemcitabine in an orthotopic pancreatic cancer model. The combination therapy substantially diminished the occurrence of either lymph node or liver metastases [29] .

Therapeutic Trials


Search
by Mechanism
PKN3-inhibitors
Advanced search
Structure search
Last 5 Searches
Refine Your Search
Indication
see all
Cancer 3
Solid tumours 2
Acute lung injury 1
Diabetes mellitus 1
Head and neck cancer 1
Phase
Discontinued 3
No development reported 1
Development Location
Europe 3
Germany 2
United Kingdom 2
England 1
3 Drugs
3 Trials
0 Safety Reports
97 Deals
0 Patents
Show Query
Share Query
Edit Query
Export
Analysis
Print Selected 0 drugs
Showing 3 of 3 drugs
Explore Graphical View
View by: List View
Sort by: Update date
Research programme: siRNA therapeutics - Silence Therapeutics
05 Apr 2022
Endothelin A receptor antagonists; Protein kinase N3 inhibitors; RNA interference; Vascular endothelial growth factor receptor-1 antagonists
Originator: Atugen AG
Inactive Indications on highest development phases
No development reported: Acute lung injury; Preeclampsia; Pulmonary arterial hypertension
Discontinued: Diabetes mellitus; Solid tumours; Wounds
Atu 027
28 Feb 2020
Protein kinase N3 inhibitors; RNA interference
Originator: Atugen AG
Inactive Indications on highest development phases
Discontinued: Head and neck cancer; Pancreatic cancer; Solid tumours
Feedback


AdisInsight
AskAdis AI New
Pharma Insight Reports New
Dashboards Beta
My Workspace
Contact Us
Help
Search
by Drug Class
SiRNA
Advanced search
Structure search
Last 5 Searches
Refine Your Search
Indication see all
Cancer 147
Liver disorders 112
Neurological disorders 105
Inflammation 96
Metabolic disorders 91
Phase see all
Marketed 5
Registered 7
Preregistration 3
Phase III 15
Phase II/III 1
Development Location see all
USA 318
Asia 169
563 Drugs
523 Trials
42 Safety Reports
57 Deals
5 Patents
Show Query
Share Query
Edit Query
Export
Analysis
Print Selected 0 drugs
Showing 10 of 563 drugs
Explore Graphical View
View by: List View
Sort by: Update date
INV 441
16 Oct 2024
Cell replacements; Immunostimulants
Active Indications (Highest Phase)
Preclinical: Glioblastoma
Originator: invIOs
No Inactive Indications
LY 3962681
16 Oct 2024
Alpha-synuclein expression modulators; RNA interference
Active Indications (Highest Phase)
Phase I: Parkinson's disease
Originator: Prevail Therapeutics
No Inactive Indications
Feedback

Micromedex

È un insieme di database in lingua inglese contenenti informazioni evidence-based su farmaci e le loro interazioni, tossicologia, analisi di laboratorio e medicina alternativa.

Disponibile solo dalla sottorete della biblioteca e del dipartimento di scienze del farmaco.

IBM Micromedex®

https://www.micromedexsolutions.com/micromedex2/librarian/


IBM Micromedex®
Il Mio Abbonamento | Gateway | Training Center | Guida | Centro per il download | Esci
Pagina iniziale
Interazioni dei farmaci
Compatibilità EV
Identificazione farmaci
Confronto farmaci
NeoFax® / Pediatrics
Ricerca farmaci e dati tossicologici
Calcolatori
Trova Farmaco, Malattia, Tossicologia e altro
Tutto
Farmaco
Malattia
Tossicologia
Keyword search
Ask Watson
Search Micromedex drug information
Type a quick question...
Learn more
Ultime notizie
Libtayo(R) Plus Chemo for NSCLC
Micromedex Mobile Apps
Kineret(R) EUA for COVID-19
Content Update Highlights
Read Top News
Sostegno & Formazione
Training Center
User Guide
Micromedex Compendia Resources
Citing Micromedex
Support Request
Risorse
Avvertenze in riquadro nero
Comparative Tables
Do Not Confuse Drug List
Drug Classes
Drug Consults
REMS
Download Mobile Apps
Feedback

Risposte rapide | Risposte approfondite | Tutti i risultati

- Dosing/Administration
  - Adult Dosing
  - Pediatric Dosing
  - FDA Uses
  - Non-FDA Uses
  - Dose Adjustments
  - Administration
  - Comparative Efficacy
  - Place In Therapy
- Medication Safety
  - Contraindications
  - Precautions
  - Adverse Effects
  - Black Box Warning
  - REMS
  - Drug Interactions (single)
  - IV Compatibility (single)
  - Pregnancy & Lactation
  - Monitoring

Dosing/Administration

Adult Dosing

Stampa

Vedere 'Risposte approfondite' per i risultati dettagliati.

Important Note

- The Emergency Use Authorization for hydroxychloroquine sulfate in hospitalized adult and adolescent patients weighing 50 kg or more for suspected or confirmed COVID-19 was revoked on June 15, 2020. The FDA concluded hydroxychloroquine sulfate is unlikely to be effective in the treatment of COVID-19 and the risks of therapy (ie, serious cardiac adverse events and methemoglobinemia) do not justify continued use [2].

General Dosage Information

- Each 200-mg tablet of hydroxychloroquine sulfate is equivalent to 155 mg base [3]

Lupus erythematosus

- 200 to 400 mg orally once daily or divided twice daily [3]

Malaria

- Initial, 800 mg orally for 1 dose followed by 400 mg at 6, 24, and 48 hours after the initial dose (FDA dosage) [3]
- (Weighing greater than 31 kg) Weight-based dosage: 13 mg/kg (MAX, 800 mg) orally for 1 dose, followed by 6.5 mg/kg (MAX, 400 mg) orally at 6, 24, and 48 hours after the first dose (FDA dosage) [3]
- Concomitant medication (Plasmodium vivax or P ovale malaria), give in combination with primaquine phosphate 52.6 mg orally daily for 14 days (guideline dosage) [4]

Malaria; Prophylaxis

- 400 mg orally once weekly on the same day each week beginning 2 weeks prior to travel to malarious area, continue on same day each week while in area and for 4 weeks after leaving area (FDA dosage) [3]

Mechanism of Action

Mechanism of Action

Visualizza documento completo
Stampa

Vedere 'Risposte rapide' per i risultati riassuntivi.

A) Hydroxychloroquine Sulfate

1) Mechanism of Action

a) Hydroxychloroquine is a 4-aminoquinoline antimalarial and antirheumatic agent. The precise mechanism by which hydroxychloroquine exhibits activity against Plasmodium is not known. Hydroxychloroquine is a weak base and may exert its effect by concentrating in the acid vesicles of the parasite and inhibiting polymerization of heme. It can also inhibit certain enzymes by its interaction with DNA. The mechanisms underlying the anti-inflammatory and immunomodulatory effects of hydroxychloroquine in the treatment of rheumatoid arthritis, chronic discoid lupus erythematosus and systemic lupus erythematosus are not fully known [1]. In rheumatoid arthritis, it is thought to act as a mild immunosuppressant, inhibiting the production of rheumatoid factor and acute phase reactants. It also accumulates in white blood cells, stabilizing lysosomal membranes and inhibiting the activity of many enzymes, including collagenase and the proteases that cause cartilage breakdown [153].

2) Spectrum of Activity

a) Hydroxychloroquine is active against the erythrocytic forms of chloroquine sensitive strains of Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax. Hydroxychloroquine is not active against the gametocytes and exoerythrocytic forms including the hypnozoite stage (P vivax and P ovale) of the Plasmodium parasites [17].

3) Resistance Patterns

a) Plasmodium falciparum strains exhibiting reduced susceptibility to chloroquine also show reduced susceptibility to hydroxychloroquine. Resistance of Plasmodium parasites to chloroquine is widespread. Patients in whom chloroquine or hydroxychloroquine have failed to prevent or cure clinical malaria or parasitemia, or patients who acquired malaria in a geographic area where chloroquine resistance is known to occur should be treated with another form of antimalarial therapy [17].

Pharmacokinetics

Pharmacokinetics

Visualizza documento completo
Stampa

Vedere 'Risposte rapide' per i risultati riassuntivi.

Drug Concentration Levels

A) Hydroxychloroquine Sulfate

1) Therapeutic Drug Concentration

a) Systemic lupus erythematosus: 910 nanograms (ng)/mL [148]

1) In a multicenter, prospective study of patients with chronic or subacute systemic lupus erythematosus (n=300), complete remission occurred with significantly higher median hydroxychloroquine levels (910 ng/mL (range, less than 50 to 3057 ng/mL)) compared with partial remission (692 ng/mL (range less than 50 to 2843 ng/mL)) and treatment failure (569 ng/mL (range, less than 50 to 2242 ng/mL) [148].

2) Peak Concentration

a) Oral, single-dose, 400 mg: 1.22 nanomoles (nmol)/mL [146]

1) Mean plasma Cmax was 1.22 +/- 0.4 nmol/mL following a single 400-mg dose of hydroxychloroquine sulfate (equivalent to 310 mg hydroxychloroquine base) in 6 healthy patients [146].

b) Oral, single-dose, 200 mg; 129.6 to 244 nanograms (ng)/mL (blood); 46 to 50.3 ng/mL (plasma) [17]

1) Following a single oral dose of hydroxychloroquine sulfate 200 mg (equivalent to 155 mg hydroxychloroquine base) in healthy male volunteers, the mean whole blood Cmax was 129.6 ng/mL and the mean plasma Cmax was 50.3 ng/mL [17].

2) Mean plasma Cmax was 46 ng/mL (range, 34 to 79 ng/mL) following a single 200-mg dose of oral hydroxychloroquine sulfate (equivalent to 155 mg hydroxychloroquine base) in 5 healthy patients; while mean whole blood Cmax was 244 ng/mL (range, 188 to 427 ng/mL) [147].

3) Time to Peak Concentration

a) Oral: 2.4 to 3.74 hours [17][146][147]; 3 to 4 hours (chronic use) [17]

Toxicology

Clinical Effects

Stampa

ACETAMINOPHEN-ACUTE

- USES: Acetaminophen is a mild analgesic and antipyretic. It is available as a non-prescription single ingredient product, in many non-prescription combination products, and in prescription combination products (usually with an opioid). PHARMACOLOGY: The exact mechanism of action is not known. Acetaminophen inhibits cyclooxygenase and this likely is responsible for at least some clinical effects. TOXICOLOGY: In overdose, the usual metabolic pathways are overwhelmed, and acetaminophen is metabolized by CYP2E1 to a reactive metabolite. This metabolite can be detoxified by conjugation with glutathione, but when hepatic glutathione stores are depleted, the metabolite binds to macromolecules in the hepatocyte causing cell death and hepatic necrosis. EPIDEMIOLOGY: Acetaminophen overdose is very common, and there are several hundred deaths from acetaminophen poisoning annually in the United States. MILD TO MODERATE TOXICITY: For the first day after ingestion, patients may be asymptomatic, or only develop nausea, vomiting and abdominal pain. Elevation of serum transaminase (ALT, AST) may begin to develop as soon as 12 hours after ingestion and can range from mild to marked (greater than 10,000 International Units/L) with few other signs or symptoms. Aminotransferase elevations generally peak 2 to 3 days after ingestion. SEVERE TOXICITY: Liver failure, including coagulopathy and hepatic encephalopathy, will occur. Patients may also have renal injury. Massive overdose (initial serum concentration greater than 500 mcg/mL) can produce coma, hyperglycemia, methemoglobinemia, and lactic acidosis In patients who survive the overdose, both hepatic and renal function usually return to normal. ADVERSE EFFECTS: Generally rare. Some patients may have gastrointestinal upset.

ACETAMINOPHEN-REPEATED SUPRATHERAPEUTIC

- USES: Acetaminophen is a non-opioid analgesic and antipyretic medication found in many over-the-counter and prescription products. Repeated supratherapeutic acetaminophen ingestion is defined as repetitive ingestion of more than the recommended maximum daily dose. These ingestions are usually unintentional occurring in patients with acute or chronic pain syndromes or repeated dosing in ill children. PHARMACOLOGY: Acetaminophen is used primarily as an antipyretic and analgesic. Its effects are mediated through the central nervous system. TOXICOLOGY: In therapeutic doses, about 90% of acetaminophen is conjugated in the liver to nontoxic metabolites (glucuronides and sulfates). A small portion (less than 5%) is conjugated by cytochrome P450 CYP2E1 to a toxic metabolite, N-acetyl-p-benzo-quinone imine (NAPQI). This metabolite is further conjugated by glutathione, and eliminated by the kidneys. In toxic doses, the usual metabolic pathways are overwhelmed; acetaminophen is shunted to the cytochrome P450 pathway, and glutathione stores are depleted. Cellular injury and hepatic necrosis occur as NAPQI accumulates. EPIDEMIOLOGY: Acetaminophen poisoning is very common and can be severe. However, the incidence of serious acetaminophen toxicity after repeated doses is negligible and appears to only follow massive dosing or prolonged excessive dosing. MILD TO MODERATE TOXICITY: Toxicity can range from asymptomatic ALT elevation to malaise, nausea, vomiting, abdominal pain, and hepatotoxicity. SEVERE TOXICITY: Jaundice, hypoglycemia, coagulopathy, renal failure,

Medication Safety

Drug Interactions (single)

Stampa

Vedere 'Risposte approfondite' per i risultati dettagliati.

Visualizza interazioni multiple del

Migliora in base a: Gravità: All Documentazione: All

Passa a: Drug-Drug (2) | ALLERGIA (0) | CIBO (0) | ETANOLO (0) | LAB (0) | TABACCO (0) | GRAVIDANZA (1) | ALLATTAMENTO (1)

Drug-Drug Interazioni (2)

Farmaci:	Gravità:	Documentazione:	Riepilogo:
CHLOROQUINE [Systemic] -- REMDESIVIR [Systemic]	Major	Fair	Concurrent use of CHLOROQUINE and REMDESIVIR may result in risk of reduced antiviral activity of remdesivir.
HYDROXYCHLOROQUINE [Systemic] -- REMDESIVIR [Systemic]	Major	Fair	Concurrent use of HYDROXYCHLOROQUINE and REMDESIVIR may result in risk of reduced antiviral activity of remdesivir.

Drug-ALLERGIA Interazioni (Nessuna trovata)

Drug-CIBO Interazioni (Nessuna trovata)

Drug-TABACCO Interazioni (Nessuna trovata)

Drug-GRAVIDANZA Interazioni (1)

Farmaci:	Gravità:	Documentazione:	Riepilogo:
PREGNANCY -- REMDESIVIR [Systemic]	Moderate	Unknown	Available evidence is inconclusive or inadequate for determining fetal risk when used in pregnant women.

Drug-ALLATTAMENTO Interazioni (1)

Farmaci:	Gravità:	Documentazione:	Riepilogo:
LACTATION -- REMDESIVIR [Systemic]	Major	Unknown	Infant risk cannot be ruled out: Available evidence and/or expert consensus is inconclusive or is inadequate for determining infant risk when Remdesivir is used during breast-feeding. Weigh the potential benefits of treatment against potential risks before prescribing Remdesivir during breast-feeding.

Definizioni

Gravità:	Controindicato	Di grande entità	Moderata	Di lieve entità	Sconosciuta
Documentazione:	Eccellente	Buona	Discreta	Sconosciuta	

Inflammatory bowel disease; Crohn's disease

Risposte rapide | Risposte approfondite | Tutti i risultati

Background

Epidemiology

Visualizza documento completo
Stampa

Incidence and Prevalence

The incidence of Crohn disease in the United States is about 5 per 100,000 persons and the prevalence is about 50 per 100,000 persons [2].

Age

Crohn disease can affect any age group [2], but has a peak onset in persons between the ages of 15 to 30 years [3].

Race and Ethnicity

In North America, the highest prevalence rates of Crohn disease are found in whites (about 44 per 100,000) and African-Americans (about 30 per 100,000) with the lowest rates found in Asians (about 6 per 100,000) and Hispanics (about 4 per 100,000) [4].

Crohn disease is more common in persons with Ashkenazi Jewish ancestry. The children of North American Ashkenazi Jews with Crohn disease appear to have an earlier onset of the disease [4].

Geography

The incidence of Crohn disease varies according to geographic location with higher rates occurring in more developed countries such as the United Kingdom, northern Europe, and North America, and lower rates occurring in developing countries. Southeast Asia, Africa, South America, and Australia have the lowest incidence rates [4]; however, the incidence is rising in less-developed countries with the expansion of industrialization [5].


Pagina iniziale
Interazioni dei farmaci
Compatibilità EV
Identificazione farmaci
Confronto farmaci
NeoFax® / Pediatrics
Ricerca farmaci e dati tossicologici
Calcolatori
Drug Monographs
Enteral Formulas
Dosing Calculators
Dosing Calculators - Patient Information
Birthdate: (MM/DD/YYYY)
MM/DD/YYYY
Population Type:
Pediatric
Age
Today
Current Weight:
kg
Proceed to Calculator


Pagina iniziale
Interazioni dei farmaci
Compatibilità EV
Identificazione farmaci
Confronto farmaci
NeoFax® / Pediatrics
Ricerca farmaci e dati tossicologici
Calcolatori
Calculators
All Calculators
Alphabetical Order
By Category
Frequent Use Calculators
Unit and Dose Converters
Medical Equations
Clinical Criteria
Decision Trees
By Specialty
All Specialties
Pharmacology
Nursing
Medical Statistics
By Category
Frequent Use Calculators
Antidote Dosing And Nomograms
Blood Ethanol Concentration Estimation
Acetaminophen (Paracetamol) Toxicity Assessment
NAC Dosing for Acetaminophen Overdose
Ethanol - Initial IV Dosing for Methanol/Ethylene Glycol Overdose
Ethanol - IV Dosing Adjustment for Methanol/Ethylene Glycol Overdose
Dosing Tools
ACLS: Adult Emergency Drug Dosing Calculator
PALS: Pediatric Emergency Drug Dosing Calculator
Heparin Dosing Calculator
IV Drip Maintenance Rate Calculator
Maintenance Fluid Calculation for Children Based on Hourly Fluid Requirements
Maintenance fluid calculation for children based on daily fluid requirements

DrugBank

DrugBank è una banca dati fattuale,gratuita di ambito farmacologico.
DrugBank Online è un database online completo e gratuito che contiene informazioni su farmaci e target.
Alcune funzioni accessibili solo registrando un account gratuito.

https://go.drugbank.com/


Smarter, Faster Drug Development with DrugBank+
Reserve Your Spot Now
DRUGBANK Online
Explore
For Drug Discovery
For Clinical Software
For Academic Research
LOG IN
Type your search...
essential drug information below, or:
Unlock enhanced features & extensive drug insights, including detailed interaction data & regulatory status. Create a free account.
Explore the full scope of our drug knowledge tailored for pharmaceutical research needs in our data library. Learn more.
Identification
Pharmacology
Interactions
Products
Categories
Chemical Identifiers
References
Clinical Trials
Pharmacoeconomics
Properties
Targets (1)
Enzymes (1)
Summary
Certolizumab pegol is a tumor necrosis factor (TNF) blocker used to treat a variety of autoimmune and autoinflammatory conditions like Crohn's disease, rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, axial spondyloarthritis, and plaque psoriasis.
Brand Names
Cimzia
Generic Name
Certolizumab pegol
DrugBank Accession Number
DB08904
Background
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha).[1] It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life.[3]


TARGETS
Product Highlight: DrugBank Data Dictionary Read Now!
Explore
For Drug Discovery
For Clinical Software
For Academic Research
LOG IN
Type your search...
1. Tumor necrosis factor
Details
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Neutralizer
General Function
Cytokine that binds to TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. It is mainly secreted by macrophages and can induce cell death of certain tumor cell lines. It is potent pyrogen causing fever by direct action or by stimulation of interleukin-1 secretion and is implicated in the induction of cachexia, Under certain conditions it can stimulate cell proliferation and induce cell differentiation. Impairs regulatory T-cells (Treg) function in individuals with rheumatoid arthritis via FOXP3 dephosphorylation. Up-regulates the expression of protein phosphatase 1 (PP1), which dephosphorylates the key 'Ser-418' residue of FOXP3, thereby inactivating FOXP3 and rendering Treg cells functionally defective

Materiali ulteriori disponibili in biblioteca: repertori

MEDICAMENTA

È una fonte di informazione esauriente e in lingua italiana sui principi attivi e su ogni molecola impiegata in terapia: denominazione, caratteristiche chimico-fisiche, saggi di identificazione e purezza, tossicità, controindicazioni...

Formato cartaceo (versione online con pw accesso dalla biblioteca e dai laboratori)

MEDICAMENTA

http://www.medicamenta.com/it

MEDICAMENTA
Società Cooperativa Farmaceutica

HOME LOGOUT

Ricerca:

- Principi attivi
- Nomi commerciali
- Categorie terapeutiche
- Preparazioni
- Nomi e sinonimi
- CAS
- ATC
- HELP

A B C D E F G I J K L M N O P Q R S T U V W

FELBAMATO

2-Fenil-1,3-propandiolo dicarbammato

$C_{11}H_{14}N_2O_4$



pm 238,24

CAS 25451-15-4

Sinonimi : 2-feniltrimetilene estere dell'acido carbammico; AD-03055

DCI felbamate

INN felbamate

Brevetti : U.S., 2 884 444, 1959; U.S., 4 978 680, 1990

Proprietà chimico-fisiche - Polvere bianca, inodore. Moderatamente solubile in acqua, in metanolo, in etanolo, in acetone e in cloroformio; molto solubile in dimetilsulfossido e in dimetilformamide.

p.f. = 151-152 °C

Proprietà farmacologiche - Il felbamato è un farmaco anticonvulsivante strutturalmente correlato al meprobamato, ma differente dal punto di vista farmacologico. L'esatto meccanismo d'azione non è noto, anche se il farmaco sembra agire innalzando la soglia delle convulsioni e prevenendo la loro diffusione. Nell'animale da laboratorio il felbamato protegge dalle convulsioni indotte da stimolazione elettrica facendo presupporre una sua efficacia nel trattamento dell'epilessia tonico-clonica (grande male) e parziale. Sempre nell'animale, il farmaco previene le convulsioni indotte da pentilentetrazolo (e quindi può essere efficace nel trattamento delle crisi di assenza nel piccolo male), picrotossina, glutammato, mentre non riesce a prevenire le convulsioni indotte da bicucullina o stricnina.

Farmacocinetica - Il felbamato è ben assorbito dal tratto gastrointestinale e le concentrazioni plasmatiche massime vengono raggiunte 1-6 ore dopo la somministrazione orale. Alle dosi raccomandate la cinetica del felbamato è lineare e le concentrazioni plasmatiche terapeutiche sono comprese tra 20 e 100 mg/ml. Il legame con le proteine plasmatiche è del 22-36%, il volume di distribuzione è di 0,76-0,8 *l*/kg e l'emivita di eliminazione è compresa tra 14 e 23 ore. Il felbamato viene parzialmente metabolizzato nel fegato, per idrossilazione e coniugazione, dando luogo a prodotti inattivi. Viene escreto principalmente nelle urine dove si ritrova sia in forma immodificata (49%) che come metaboliti; l'escrezione nelle feci è inferiore al 4%. Nel ratto il felbamato attraversa la barriera placentare e viene escreto nel latte materno.

Tossicità - Nel topo il valore della DL_{50} per i.p. è di 4000 mg/kg.

Indicazioni terapeutiche - Nell'adulto il felbamato viene usato, sia in monoterapia che come farmaco aggiuntivo, nel trattamento delle convulsioni parziali resistenti, con o senza generalizzazione secondaria. Nel bambino il felbamato può essere usato come farmaco aggiuntivo per controllare le convulsioni associate alla sindrome di Lennox-Gastaut. A causa della sua tossicità il felbamato non deve essere considerato un farmaco di prima scelta e dovrebbe essere usato solo nel trattamento di pazienti che non rispondono ad altri farmaci o che siano intolleranti a essi.

Pubchem

Pubchem è una banca dati fattuale,gratuita di ambito chimico.
Si trovano informazioni su strutture chimiche, identificatori, proprietà chimiche e fisiche, attività biologiche, brevetti, dati su salute, sicurezza, tossicità etc.

https://pubchem.ncbi.nlm.nih.gov/



COMPOUND SUMMARY

Aspirin

PubChem CID	2244
Structure	2D 3D Crystal Find Similar Structures
Chemical Safety	Irritant Laboratory Chemical Safety Summary (LCSS) Datasheet
Molecular Formula	$C_9H_8O_4$ or $CH_3COOC_6H_4COOH$ or $HC_9H_7O_4$
Synonyms	aspirin ACETYLSALICYLIC ACID 50-78-2 2-Acetoxybenzoic acid 2-(Acetyloxy)benzoic acid More...
Molecular Weight	180.16
Dates	Modify 2021-10-16 Create 2004-09-16

Aspirin or acetylsalicylic acid is perhaps the most commonly used analgesic and antipyretic medication worldwide, having been in clinical use for over 100 years. Aspirin can cause several forms of liver injury: in high doses, aspirin can cause moderate to marked serum aminotransferase elevations occasionally with jaundice or signs of liver dysfunction, and in lower doses in susceptible children with a febrile illness aspirin can lead to Reye syndrome.

▸ LiverTox

Aspirin is an orally administered non-steroidal antiinflammatory agent. Acetylsalicylic acid binds to and acetylates serine residues in cyclooxygenases, resulting in decreased synthesis of prostaglandin, platelet aggregation, and inflammation. This agent exhibits analgesic, antipyretic, and anticoagulant properties.

▸ NCI Thesaurus (NCIt)

Also known as *Aspirin*, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI). Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer. Aspirin is classified as a *non-selective cyclooxygenase (COX) inhibitor* and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others. Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants.

▸ DrugBank

Cite Download

CONTENTS

- Title and Summary
- 1 Structures
- 2 Names and Identifiers
- 3 Chemical and Physical Properties
- 4 Spectral Information
- 5 Related Records
- 6 Chemical Vendors
- 7 Drug and Medication Information
- 8 Pharmacology and Biochemistry
- 9 Use and Manufacturing
- 10 Identification
- 11 Safety and Hazards
- 12 Toxicity
- 13 Associated Disorders and Diseases
- 14 Literature
- 15 Patents
- 16 Biomolecular Interactions and Pathways
- 17 Biological Test Results



PubChem Aspirin (Compound)

▸ The National Institute for Occupational Safety and Health (NIOSH)

3.2.2 Color/Form

Monoclinic tablets or needle-like crystals

O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc., 2006, p. 140

▸ Hazardous Substances Data Bank (HSDB)

Colorless to white, crystalline powder.

NIOSH. NIOSH Pocket Guide to Chemical Hazards & Other Databases CD-ROM. Department of Health & Human Services, Centers for Disease Prevention & Control. National Institute for Occupational Safety & Health. DHHS (NIOSH) Publication No. 2005-151 (2005)

▸ Hazardous Substances Data Bank (HSDB)

3.2.3 Odor

Odorless, but in moist air it is gradually hydrolyzed and acquires odor of acetic acid

O'Neil, M.J. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc., 2006, p. 140

▸ Hazardous Substances Data Bank (HSDB)

Odorless [Note: Develops the vinegar-like odor of acetic acid on contact with moisture].

NIOSH. NIOSH Pocket Guide to Chemical Hazards & Other Databases CD-ROM. Department of Health & Human Services, Centers for Disease Prevention & Control. National Institute for Occupational Safety & Health. DHHS (NIOSH) Publication No. 2005-151 (2005)

▸ Hazardous Substances Data Bank (HSDB)

3.2.4 Boiling Point

Cite Download

CONTENTS

- Title and Summary
- 1 Structures
- 2 Names and Identifiers
- 3 Chemical and Physical Properties
- 4 Spectral Information
- 5 Related Records
- 6 Chemical Vendors
- 7 Drug and Medication Information
- 8 Pharmacology and Biochemistry
- 9 Use and Manufacturing
- 10 Identification
- 11 Safety and Hazards
- 12 Toxicity
- 13 Associated Disorders and Diseases
- 14 Literature
- 15 Patents
- 16 Biomolecular Interactions and Pathways
- 17 Biological Test Results
- 18 Classification

EUROPEAN PHARMACOPOEIA

È il codice farmaceutico che armonizza i testi delle principali farmacopee ufficiali degli Stati Europei e individua norme comuni riconosciute sulla qualità dei medicinali.

Complesso di disposizioni tecnico/scientifiche ed amministrative, per il controllo della qualità dei medicamenti, delle sostanze e/o dei preparati finali, mediante l'indicazione di metodi di verifica chimico analitici e tecnologici delle specifiche di qualità, dei metodi di preparazione o della formulazione.

In formato cartaceo ma anche online con pw (solo per docenti e laureandi..)

https://pheur.edqm.eu/home

banca dati	ambito disciplinare	citazionale e bibliografica	fattuale	a pagamento	gratuita
Scopus	multidisciplinare	x		x	
Web of Science	multidisciplinare	x		x	
Pubmed	biomedico	bibliografica			x
Pubchem	chimico		x		x
Codifa	farmaceutico		x	x	
Micromedex	farmaceutico		x	x	
AdisInsight	farmaceutico		x	x	
DrugBank	farmaceutico		x		x

Cosa cerco e dove lo trovo

Tipo di ricerca	Dove cercare
Sostanza	Pubchem, Medicamenta, European Pharmacopoeia, Farmacopea italiana
Farmaco	Codifa, Medicamenta, Micromedex,AdisInsight, DrugBank
Tossicità ed effetti collaterali	Codifa, Micromedex, Pubchem, DrugBank
Farmacodinamica/cinetica	Pubmed, Micromedex, Codifa, DrugBank
Studi clinici	Pubmed, AdisInsight
Interazioni farmacologiche	Codifa, Micromedex, Pubmed
letteratura scientifica	Pubmed, Scopus e WOS

...e queste sono solo le principali, ce ne sono ancora molte altre.
Se hai bisogno chiedi aiuto in biblioteca!

pch.vector-freepik.com

...problemi con la tesi?
Prendi appuntamento con un bibliotecario!